Prognostic value of fluorescence in situ hybridization (FISH) in patients with chronic lymphocytic leukemia

Abstract

Flourescencijska in situ hibridizacija omogućila je detekciju citogenetskih promjena u bolesnika s kroničnom limfocitnom leukemijom. Ova metoda koristi se u dijagnostičkoj obradi bolesnika prije inicijacije kemoimunoterapije. Ova retrospektivna studija obuhvatila je 70 novodijagnosticiranih bolesnika u razdoblju između 2013. i 2017. godine s ciljem praćenja ishoda bolesti, odnosno brzine progresije bolesti i odgovora na konvencionalnu terapiju u odnosu na nalaz citogenetskih promjena, uzimajući u obzir i druge prognostičke čimbenike dobi, spola te kliničkog stadija. Citogenetske promjene nađene su u 20 bolesnika. Najčešći nalaz bila je delecija 13q14 (16%), zatim 17p (9%), dok su delecija 11p i trisomija 12 nađene u samo jednog bolesnika. Iako je broj bolesnika s nađenim citogenetskim promjenama bio malen, nađene su statistički značajne razlike u OS-u i PFS-u među skupinama, gdje se istaknula delecija 17p kao citogenetska promjena najlošijeg ishoda.Flourescence in situ hybridization has improved the detection of genomic aberrations in patients with chronic lymphocytic leukemia (CLL). This method is used to identify chromosomal abnormalities in patients with CLL before treating a patient on protocol . We applied FISH to blood smear samples from all newly diagnosed patients with CLL in the period from 2013 to 2017. Overall survival and progression free survival in 70 patients were analysed to evaluate prognosis regarding chromosomal aberrations, age, gender, Binet and Rai stage. Chromosomal aberrations were found in 20 of 70 patients. Most frequent aberrations were deletions in 13q14 (16%), 17p (9%), while deletion 11q and trisomy 12 were found in one patient. Patients with 17p deletion had the shortest progression free survival and overall survival. In conclusion, FISH is an important prognostic factor of disease progression and overall survival